MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers

被引:21
作者
Cui, Shi-Yun [1 ]
Wang, Rui [1 ]
Chen, Long-Bang [1 ]
机构
[1] Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, Nanjing 210002, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
microRNA; taxane; chemoresistance; apoptosis; cell cycle; epithelial-mesenchymal transition; ATTENUATES PACLITAXEL-RESISTANCE; LUNG ADENOCARCINOMA CELLS; TAXOL-INDUCED APOPTOSIS; BETA-TUBULIN ISOTYPES; BREAST-CANCER; PROSTATE-CANCER; OVARIAN-CANCER; MULTIDRUG-RESISTANCE; TUMOR-CELLS; IN-VITRO;
D O I
10.1111/jcmm.12131
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The successful long-term use of taxane for cancer therapy is often prevented by the development of drug resistance in clinic. Thus, exploring the mechanisms involved is a first step towards rational strategies to overcome taxane resistance. Taxane resistance-related microRNA (miRNAs) are under investigation and miRNAs could induce the taxane resistance of tumour cells by regulating cell cycle distribution, survival and/or apoptosis pathways, drug transports, epithelial-mesenchymal transition and cancer stem cell. This article summarizes current research involving miRNAs as regulators of key target genes for tanxanxe chemoresistance and discusses the complex regulatory networks of miRNAs. Also, the authors will envisage future developments towards the potential use of targeting miRNAs as a novel strategy for improving response of tumour patients to taxane. miRNAs play critical roles in taxane chemoresistance and the miRNA-based therapies will be helpful for overcoming drug resistance and developing more effective personalized anti-cancer treatment strategies. Further research studies should be performed to promote therapeutic-clinical use of taxane resistance-related miRNAs in cancer patients, especially in those patients with taxane-resistant cancers.
引用
收藏
页码:1207 / 1217
页数:11
相关论文
共 111 条
  • [1] Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
    Abal, M.
    Andreu, J. M.
    Barasoain, I.
    [J]. CURRENT CANCER DRUG TARGETS, 2003, 3 (03) : 193 - 203
  • [2] Adenomatous polyposis coli (APC):: a multi-functional tumor suppressor gene
    Aoki, Koji
    Taketo, Makoto M.
    [J]. JOURNAL OF CELL SCIENCE, 2007, 120 (19) : 3327 - 3335
  • [3] Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
    Bacus, SS
    Gudkov, AV
    Lowe, M
    Lyass, L
    Yung, Y
    Komarov, AP
    Keyomarsi, K
    Yarden, Y
    Seger, R
    [J]. ONCOGENE, 2001, 20 (02) : 147 - 155
  • [4] Do β-tubulin mutations have a role in resistance to chemotherapy?
    Berrieman, HK
    Lind, MJ
    Cawkwell, L
    [J]. LANCET ONCOLOGY, 2004, 5 (03) : 158 - 164
  • [5] BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623
  • [6] Blagosklonny MV, 1997, CANCER RES, V57, P130
  • [7] MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy
    Boren, Todd
    Xiong, Yin
    Hakam, Ardeshir
    Wenham, Robert
    Apte, Sachin
    Chan, Gina
    Kamath, Siddharth G.
    Chen, Dung-Tsa
    Dressman, Holly
    Lancaster, Johnathan M.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 113 (02) : 249 - 255
  • [8] Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1
    Boyerinas, Benjamin
    Park, Sun-Mi
    Murmann, Andrea E.
    Gwin, Katja
    Montag, Anton G.
    Zillhardt, Marion
    Hua, You-Jia
    Lengyel, Ernst
    Peter, Marcus E.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (08) : 1787 - 1797
  • [9] The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?
    Brabletz, Simone
    Brabletz, Thomas
    [J]. EMBO REPORTS, 2010, 11 (09) : 670 - 677
  • [10] The role of β-tubulin isotypes in resistance to antimitotic drugs
    Burkhart, CA
    Kavallaris, M
    Horwitz, SB
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1471 (02): : O1 - O9